Bide Pharmaceuticals released its 2024 annual performance, with a net profit attributable to the parent company of 117 million yuan, a year-on-year increase of 7.17%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Bide Pharmaceuticals disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; net profit attributable to the parent company was 117 million yuan, a year-on-year increase of 7.17%; net profit excluding non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 15.09%; basic earnings per share were 1.32 yuan. The company plans to distribute a cash dividend of 9.00 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, Bide (688073.SH) disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; net profit attributable to shareholders was 117 million yuan, a year-on-year increase of 7.17%; net profit excluding non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 15.09%; basic earnings per share were 1.32 yuan. The company plans to distribute a cash dividend of 9.00 yuan (including tax) for every 10 shares to all shareholders